Mainz Biomed (NASDAQ:MYNZ – Get Free Report) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.
Valuation & Earnings
This table compares Mainz Biomed and TetraLogic Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Mainz Biomed | $895,479.00 | 3.89 | -$26.30 million | ($1.64) | -0.18 |
TetraLogic Pharmaceuticals | N/A | N/A | N/A | N/A | N/A |
TetraLogic Pharmaceuticals has lower revenue, but higher earnings than Mainz Biomed.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Mainz Biomed | -2,934.82% | -488.05% | -145.77% |
TetraLogic Pharmaceuticals | N/A | N/A | N/A |
Analyst Recommendations
This is a summary of recent ratings and price targets for Mainz Biomed and TetraLogic Pharmaceuticals, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Mainz Biomed | 0 | 1 | 1 | 0 | 2.50 |
TetraLogic Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Mainz Biomed presently has a consensus price target of $3.00, indicating a potential upside of 934.48%.
Institutional & Insider Ownership
0.0% of TetraLogic Pharmaceuticals shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 15.4% of TetraLogic Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
TetraLogic Pharmaceuticals beats Mainz Biomed on 4 of the 7 factors compared between the two stocks.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.